Genes Affect Plasma
Levels of Lipids

AtheroGxOne™ is a comprehensive 84-gene
genetic test to aid in the risk assessment and
diagnosis of early atherosclerosis/dyslipidemias

Sample Report
Information Sheet

Genes Affect Plasma
Levels of Lipids

AtheroGxOne™ is a comprehensive 84-gene
genetic test to aid in the risk assessment and
diagnosis of early atherosclerosis/dyslipidemias

Sample Report
Information Sheet
AtheroGxOne_Logo-e1536074182204 AtheroGxOne™

A joint collaboration between

Joint_Collaboration-e1536074309832 AtheroGxOne™

A single test to detect mutations in 84 genes responsible for
monogenic diseases of early atherosclerosis

Cardiologists_icon-e1536074597472 AtheroGxOne™
Reports written by
cardiologists; not
genetic counselors
rapid_turnaround_icon-e1536074635901 AtheroGxOne™
Rapid
Turnaround
Time
adhered_medical_guidelines_icon-e1536074646933 AtheroGxOne™
Adheres to
medical
guidelines
Cost_Savings_icon-e1536074664626 AtheroGxOne™
Early intervention
leads to significant
cost savings

A single test to detect mutations in 84 genes responsible for
monogenic diseases of early atherosclerosis

Cardiologists_icon-e1536084759712 AtheroGxOne™
Reports written by cardiologists; not genetic counselors
rapid_turnaround_icon-e1536084741526 AtheroGxOne™
Rapid Turnaround Time
adhered_medical_guidelines_icon-e1536084720657 AtheroGxOne™
Adheres to medical guidelines
Cost_Savings_icon-e1536084703175 AtheroGxOne™
Early intervention leads to significant cost savings

A single test to detect mutations in 84 genes responsible for monogenic diseases of early atherosclerosis

Cardiologists_icon-e1536084759712 AtheroGxOne™
Reports written by
cardiologists; not
genetic counselors
rapid_turnaround_icon-e1536084741526 AtheroGxOne™
Rapid
Turnaround
Time
adhered_medical_guidelines_icon-e1536084720657 AtheroGxOne™
Adheres to
medical
guidelines
Cost_Savings_icon-e1536084703175 AtheroGxOne™
Early intervention
leads to significant
cost savings

Covered conditions include the following

Cardiomyopathies-1-150x150 AtheroGxOne™

Premature Coronary
Artery Disease

Atheroscierotic-150x150 AtheroGxOne™

Familial
Hypercholesterolemia

Familial_Hypertriglyceridemia-150x150 AtheroGxOne™

Familial
Hypertriglyceridemia

The FH Foundation recommends cascade
screening for those with definite or probable FH.

Cascade_Screening-e1536075506264 AtheroGxOne™

What is Cascade Screening?

“The identification of close relatives of an
individual with a disorder to determine
whether the relatives are also affected or
are carriers of the same disorder. The
process begins with the identification of
an individual with the condition and/or a
pathogenic variant associated with the
condition and then extending genetic
testing to his/her at-risk biological
relatives. This process is repeated as more
affected individuals or pathogenic variant
carriers are identified.” ¹

The FH Foundation recommends cascade
screening for those with definite or probable FH.

Cascade_Screening-e1536075506264 AtheroGxOne™

What is Cascade Screening?

“The identification of close relatives of an individual with a disorder to determine whether the relatives are also affected or are carriers of the same disorder. The process begins with the identification of an individual with the condition and/or a pathogenic variant associated with the condition and then extending genetic testing to his/her at-risk biological relatives. This process is repeated as more affected individuals or pathogenic variant carriers are identified.” ¹

FH Foundation Clinical Guidelines

The world’s leading cardiologists assess the utility of FH genetic testing. They determined: 2

Pathogenic variants indicate higher cardiovascular risk, which indicates the potential need for more aggressive lipid lowering
Facilitation of
definitive diagnosis

FH Genetic Testing

Increase in initiation of and adhere to therapy
Cascade testing of relatives

FH Foundation Clinical Guidelines

The world’s leading cardiologists assess the utility of FH genetic testing. They determined: 2

1. Facilitation of definitive diagnosis

2. Pathogenic variants indicate higher
cardiovascular risk, which indicates the
potential need for more aggressive lipid lowering

3. Increase in initiation of and adhere to therapy

4. Cascade testing of relatives

Proprietary Database

Proprietary_Database-e1536241911932 AtheroGxOne™

35,000 papers on inherited
cardiovascular diseases (400
added monthly)

153,000 individuals

Approximately 65,000 families

500,176 genetic variants

Proprietary Database

Proprietary_Database-e1536241796559 AtheroGxOne™

35,000 papers on inherited
cardiovascular diseases (400
added monthly)

153,000 individuals

Approximately 65,000 families

500,176 genetic variants

Clear and Actionable Reports

Clinical interpretation created by team of leading cardiologists

View Sample Report
AtheroGxOne_Report_Thumbnail-e1536075868106 AtheroGxOne™

Complements Admera Health’s Cardiovascular Test Portfolio

CardioGxOne_logo AtheroGxOne™

A comprehensive 213-gene genetic test that provides expert analysis on a broad scope of conditions
(e.g. cardiomyopathies, aortic syndromes, channelopathies & arrythmias, and more)

Learn more
pgxcardio-sm AtheroGxOne™

Genetic testing for optimizing cardiovascular drug
therapy. Improve cardiovascular treatment from
diagnosis to outcome

Learn more

Complements Admera Health’s Cardiovascular Test Portfolio

CardioGxOne_logo AtheroGxOne™

A comprehensive 213-gene genetic test that provides expert analysis on a broad scope of conditions (e.g. cardiomyopathies, aortic syndromes, channelopathies & arrythmias, and many more)

Learn more
pgxcardio-sm AtheroGxOne™

Genetic testing for optimizing
cardiovasculardrug therapy.
Improve cardiovascular treatment
from diagnosis to outcome

Learn more

1. Ref: J Am Coll Cardiol. 2018 Aug 7;72(6):662-680.
2. Eur J Hum Genet. 2005 Apr;13(4):401-408. and https://www.cancer.gov/publications/dictionaries/genetics-dictionary/def/cascade-screening